Silo Pharma, Inc. (SILO) — Silo Pharma said Nasdaq confirmed that, as of June 17, 2026, it had regained compliance with the minimum closing bid price requirement under Listing Rule 5550(a)(2), removing a delisting risk.
CEO Eric Weisblum said the company continues advancing its lead PTSD candidate SPC-15 toward a first-in-human trial. Regaining compliance stabilizes the micro-cap's listing status as it pursues its neuropsychiatric pipeline.
Source: investingnews.com
For the rest of that week's sector news, read our week in review.